Fungal pathogens and COVID-19

Curr Opin Microbiol. 2023 Oct:75:102365. doi: 10.1016/j.mib.2023.102365. Epub 2023 Aug 23.

Abstract

COVID-19 pandemic highlighted the complications of secondary fungal infections that occurred globally in severe cases of coronavirus disease managed in the intensive care units. Furthermore, varied underlying host factors, such as preexisting immunosuppression, the use of immunomodulatory agents, and invasive procedures predisposing lung tissues to fungal colonization and proliferation, caused increased susceptibility to fungal infections in COVID-19 patient populations. These invasive fungal infections directly impact the overall length of hospitalization and mortality. The most commonly reported fungal infections in patients with COVID-19 include aspergillosis, invasive candidiasis, and mucormycosis. An overall worldwide increase in the prevalence of candidiasis and aspergillosis was observed in COVID-19 patients , whereas outbreaks of mucormycosis were mainly recorded from India. Diagnostic challenges and limited antifungal treatment options make secondary fungal infections among COVID-19 patients more burdensome, which results in improper management and increased mortality.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspergillosis*
  • COVID-19*
  • Candidiasis*
  • Coinfection*
  • Humans
  • Mucormycosis* / drug therapy
  • Pandemics